Skip to main content

LEN

Stock
Consumer Discretionary
Residential Construction

Performance overview

LEN Price
Price Chart

Forward-looking statistics

Beta
0.73
Risk
31.34%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for rent construction and has invested in numerous housing-related technology startups.

Company info

SectorConsumer Discretionary
IndustryResidential Construction
Employees10K
Market cap$42.8B

Fundamentals

Enterprise value$26.9B
Revenue$35.4B
Revenue per employee—
Profit margin9.21%
Debt to equity19.29

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$12.07
Dividend per share$2.00
Revenue per share$133.42
Avg trading volume (30 day)$389M
Avg trading volume (10 day)$446M
Put-call ratio—

Macro factor sensitivity

Growth+0.1
Credit+4.9
Liquidity-2.2
Inflation-2.4
Commodities+0.1
Interest Rates-2.3

Valuation

Dividend yield1.82%
PEG Ratio6.82
Price to sales0.80
P/E Ratio6.82
Enterprise Value to Revenue0.76
Price to book1.26

Upcoming events

Next earnings dayMarch 21, 2025
Next dividend day—
Ex. dividend dayJuly 3, 2025

News

5 Homebuilding Stocks To Considering Selling On Copper Tariff Threats

President Donald Trump is back on his trade war horse, announcing plans to implement 50% tariffs on imported copper on August 1st. While the chance of this 50% number being the final rate is slim, given past tariff climbdowns, copper tariffs would present a new headwind to an industry that's already fighting discouraging trends: homebuilders.

Benzinga (July 17, 2025)
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?

Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research (July 16, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free